Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
14.69
-0.13 (-0.88%)
At close: Aug 29, 2025, 4:00 PM
14.50
-0.19 (-1.29%)
After-hours: Aug 29, 2025, 6:46 PM EDT

Company Description

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.

It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease.

The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant, Inc.
Immunovant logo
CountryUnited States
Founded2018
IndustryBiotechnology
SectorHealthcare
Employees362
CEOEric Venker

Contact Details

Address:
320 West 37th Street, 6th Floor
New York, New York 10018
United States
Phone917 580 3099
Websiteimmunovant.com

Stock Details

Ticker SymbolIMVT
ExchangeNASDAQ
Fiscal YearApril - March
Reporting CurrencyUSD
CIK Code0001764013
CUSIP Number45258J102
ISIN NumberUS45258J1025
Employer ID83-2771572
SIC Code2836

Key Executives

NamePosition
Dr. Eric Venker M.D., Pharm.D.Chief Executive Officer and Director
Dr. Frank M. Torti M.B.A., M.D.Executive Chairperson of the Board
Melanie Gloria B.S.N.Chief Operating Officer
Christopher A. Van Tuyl Esq., J.D.Chief Legal Officer and Corporate Secretary
Dr. Michael Geffner M.B.A., M.D., Ph.D.Chief Medical Officer
Tiago M. Girao CPAChief Financial Officer
Dr. Jay S. Stout Ph.D.Chief Technology Officer
Christine BlodgettSenior Vice President of Human Resources
Lauren Schrier M.B.A.Vice President and Head of Global Medical Affairs
Andy DeigSenior Vice President of Strategic Finance

Latest SEC Filings

DateTypeTitle
Aug 28, 20258-KCurrent Report
Aug 11, 202510-QQuarterly Report
Aug 11, 20258-KCurrent Report
Jul 29, 20258-KCurrent Report
Jul 9, 2025ARSFiling
Jul 9, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 9, 2025DEF 14AOther definitive proxy statements
Jun 25, 2025144Filing
Jun 13, 2025144Filing
Jun 3, 2025144Filing